Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal Study of Aging.
OBJECTIVE
Although hyperglycemia is thought to increase the generation of advanced glycation end products (AGEs), studies have not shown a consistent relationship between abnormal glucose metabolism and serum AGEs. We investigated the relationship between a dominant serum AGE, N-carboxymethyl-lysine (CML), and glucose metabolism.


METHODS
Serum CML, fasting plasma glucose, and glucose tolerance were measured in 755 adults in the Baltimore Longitudinal Study of Aging. Fasting plasma glucose was categorized as normal (< or = 99 mg/dL), impaired (100-125 mg/dL), and diabetic (> 125 mg/dL). Two-hour plasma glucose on oral glucose tolerance testing was categorized as normal (< or = 139 mg/dL), impaired (140-199 mg/dL), and diabetic (> or = 200 mg/dL).


RESULTS
The proportion of adults with normal, impaired, and diabetic fasting plasma glucose was 73.8%, 22.9%, and 2.9%, respectively, and the proportion with normal, impaired, and diabetic 2-hour plasma glucose was 73.1%, 19.2%, and 7.7%, respectively. Serum CML (microg/mL) was not associated with abnormal fasting plasma glucose (Odds Ratio [O.R.] 0.60, 95% Confidence Interval [C.I.] 0.15-2.36, P = 0.47) in a multivariate, ordered logistic regression model, adjusting for age, race, gender, body mass index, and chronic diseases. Serum CML (microg/mL) was associated with abnormal 2-hour plasma glucose on glucose tolerance testing (O.R. 0.15, 95% C.I. 0.04-0.63, P = 0.009) in a multivariate, ordered logistic regression model, adjusting for the same covariates.


CONCLUSIONS
Elevated CML, a dominant AGE, was not associated with elevated fasting plasma glucose and was associated with a reduced odds of abnormal glucose tolerance in older community-dwelling adults.
Semba
R D
RD
Johns Hopkins School of Medicine, Baltimore, MD 21287, USA. rdsemba@jhmi.edu
Beck
J
J
Sun
K
K
Egan
J M
JM
Carlson
O D
OD
Varadhan
R
R
Ferrucci
L
L
D000368:Aged; D015142:Baltimore; D001786:Blood Glucose / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000097:blood; D005260:Female; D018149:Glucose Intolerance / Q000097:blood*; D005951:Glucose Tolerance Test; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D016015:Logistic Models; D008239:Lysine / Q000031:analogs & derivatives* / Q000097:blood; D008297:Male; D008875:Middle Aged
D001786:Blood Glucose; D017127:Glycation End Products, Advanced; C048496:N(6)-carboxymethyllysine; D008239:Lysine
Am J Clin Nutr. 2007 May;85(5):1236-43
17490958
Biochim Biophys Acta. 2004 Mar 22;1636(2-3):82-9
15164755
Clin Chem Lab Med. 2005;43(5):503-11
15899672
Diabetes Care. 1999 Sep;22(9):1543-8
10480523
Diabetes Obes Metab. 2005 May;7(3):263-7
15811143
Eur J Nutr. 2009 Feb;48(1):38-44
19031098
Curr Diab Rep. 2007 Jun;7(3):235-41
17547841
Biochemistry. 1995 Aug 29;34(34):10872-8
7662668
Diabetes Care. 2003 Jan;26 Suppl 1:S5-20
12502614
JAMA. 2001 May 16;285(19):2486-97
11368702
Neth J Med. 2006 Jan;64(1):10-6
16421436
Diabetes Care. 1998 Nov;21(11):1997-2002
9802757
Diabet Med. 2003 Jul;20(7):575-9
12823240
Ann Intern Med. 1999 Mar 16;130(6):461-70
10075613
Diabetologia. 2004 Aug;47(8):1376-9
15258735
Am J Kidney Dis. 2003 Sep;42(3):532-8
12955681
Cardiovasc Res. 2004 Sep 1;63(4):582-92
15306213
J Am Diet Assoc. 2004 Aug;104(8):1287-91
15281050
Am J Kidney Dis. 2006 Oct;48(4):571-9
16997053
Clin Chem. 1972 Jun;18(6):499-502
4337382
J Diabetes Complications. 2003 Jan-Feb;17(1):16-21
12505751
Diabetes Care. 2002 Jun;25(6):1055-9
12032114
Diabetes Res Clin Pract. 1998 Aug;41(2):131-7
9789719
J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):427-33
17452738
Endocr J. 2004 Dec;51(6):537-44
15644571
Obes Res. 2001 Nov;9 Suppl 4:228S-233S
11707546
Clin Chem. 1982 Jun;28(6):1379-88
7074948
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6474-9
9177242
Am J Physiol Renal Physiol. 2005 Oct;289(4):F645-59
16159899
J Am Geriatr Soc. 2009 Oct;57(10):1874-80
19682127